FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083801158> ?p ?o ?g. }

• W2083801158 endingPage "6" @default.
• W2083801158 startingPage "1" @default.
• W2083801158 abstract "Objectives . To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting. Methods . Data was retrospectively collected on 178 patients with T2-T4 bladder cancer who underwent radical cystectomy between 2003 and 2011. Outcomes of interest included those with complete response (pT0) and any response (≤pT1). Odds ratios were calculated using multivariate logistic regression. Results . Compared to those who did not receive neoadjuvant chemotherapy, there were more patients with complete response (28% versus 9%, OR 3.11 (95% CI: 1.45–6.64),<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M1><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.03</mml:mn></mml:math>) and any response (52% versus 25%, OR 3.23 (95% CI: 1.21–8.64),<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M2><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:math>). Seventy-two patients received GC (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M3><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>41</mml:mn></mml:math>) or MVAC (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M4><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>31</mml:mn></mml:math>). CR was achieved in 29% and 22% of GC and MVAC patients, respectively (multivariate OR 0.39, 95% CI 0.10–1.58). Any response (≤pT1) was achieved in 56% of GC and 45% of MVAC patients (multivariate OR 0.45, 95% CI 0.12–1.71). Conclusions . We observed similar pathologic response rates for GC and MVAC neoadjuvant chemotherapy in this cohort of patients with muscle invasive urothelial cancer (MIBC). Our findings support the use of GC as an alternative regimen in the neoadjuvant setting." @default.
• W2083801158 created "2016-06-24" @default.
• W2083801158 creator A5003319562 @default.
• W2083801158 creator A5011092943 @default.
• W2083801158 creator A5023976305 @default.
• W2083801158 creator A5036837044 @default.
• W2083801158 creator A5046669491 @default.
• W2083801158 creator A5057474224 @default.
• W2083801158 creator A5060420563 @default.
• W2083801158 creator A5079308651 @default.
• W2083801158 creator A5080866168 @default.
• W2083801158 creator A5081237981 @default.
• W2083801158 creator A5084909001 @default.
• W2083801158 creator A5089665460 @default.
• W2083801158 date "2013-01-01" @default.
• W2083801158 modified "2023-10-01" @default.
• W2083801158 title "Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer" @default.
• W2083801158 cites W1538189929 @default.
• W2083801158 cites W1560239325 @default.
• W2083801158 cites W1975918912 @default.
• W2083801158 cites W1986710101 @default.
• W2083801158 cites W2026826756 @default.
• W2083801158 cites W2034679752 @default.
• W2083801158 cites W2051762085 @default.
• W2083801158 cites W2073804272 @default.
• W2083801158 cites W2078191480 @default.
• W2083801158 cites W2085828464 @default.
• W2083801158 cites W2090241022 @default.
• W2083801158 cites W2101562875 @default.
• W2083801158 cites W2103257412 @default.
• W2083801158 cites W2103561213 @default.
• W2083801158 cites W2113156769 @default.
• W2083801158 cites W2128042367 @default.
• W2083801158 cites W2336213711 @default.
• W2083801158 cites W4236466551 @default.
• W2083801158 doi "https://doi.org/10.1155/2013/317190" @default.
• W2083801158 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3871504" @default.
• W2083801158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24382958" @default.
• W2083801158 hasPublicationYear "2013" @default.
• W2083801158 type Work @default.
• W2083801158 sameAs 2083801158 @default.
• W2083801158 citedByCount "35" @default.
• W2083801158 countsByYear W20838011582013 @default.
• W2083801158 countsByYear W20838011582015 @default.
• W2083801158 countsByYear W20838011582016 @default.
• W2083801158 countsByYear W20838011582017 @default.
• W2083801158 countsByYear W20838011582018 @default.
• W2083801158 countsByYear W20838011582019 @default.
• W2083801158 countsByYear W20838011582020 @default.
• W2083801158 countsByYear W20838011582021 @default.
• W2083801158 countsByYear W20838011582022 @default.
• W2083801158 countsByYear W20838011582023 @default.
• W2083801158 crossrefType "journal-article" @default.
• W2083801158 hasAuthorship W2083801158A5003319562 @default.
• W2083801158 hasAuthorship W2083801158A5011092943 @default.
• W2083801158 hasAuthorship W2083801158A5023976305 @default.
• W2083801158 hasAuthorship W2083801158A5036837044 @default.
• W2083801158 hasAuthorship W2083801158A5046669491 @default.
• W2083801158 hasAuthorship W2083801158A5057474224 @default.
• W2083801158 hasAuthorship W2083801158A5060420563 @default.
• W2083801158 hasAuthorship W2083801158A5079308651 @default.
• W2083801158 hasAuthorship W2083801158A5080866168 @default.
• W2083801158 hasAuthorship W2083801158A5081237981 @default.
• W2083801158 hasAuthorship W2083801158A5084909001 @default.
• W2083801158 hasAuthorship W2083801158A5089665460 @default.
• W2083801158 hasBestOaLocation W20838011581 @default.
• W2083801158 hasConcept C11413529 @default.
• W2083801158 hasConcept C121608353 @default.
• W2083801158 hasConcept C126322002 @default.
• W2083801158 hasConcept C126894567 @default.
• W2083801158 hasConcept C2775910329 @default.
• W2083801158 hasConcept C2776694085 @default.
• W2083801158 hasConcept C2777132456 @default.
• W2083801158 hasConcept C2778239845 @default.
• W2083801158 hasConcept C2778292576 @default.
• W2083801158 hasConcept C2780258809 @default.
• W2083801158 hasConcept C2780352672 @default.
• W2083801158 hasConcept C41008148 @default.
• W2083801158 hasConcept C530470458 @default.
• W2083801158 hasConcept C71924100 @default.
• W2083801158 hasConceptScore W2083801158C11413529 @default.
• W2083801158 hasConceptScore W2083801158C121608353 @default.
• W2083801158 hasConceptScore W2083801158C126322002 @default.
• W2083801158 hasConceptScore W2083801158C126894567 @default.
• W2083801158 hasConceptScore W2083801158C2775910329 @default.
• W2083801158 hasConceptScore W2083801158C2776694085 @default.
• W2083801158 hasConceptScore W2083801158C2777132456 @default.
• W2083801158 hasConceptScore W2083801158C2778239845 @default.
• W2083801158 hasConceptScore W2083801158C2778292576 @default.
• W2083801158 hasConceptScore W2083801158C2780258809 @default.
• W2083801158 hasConceptScore W2083801158C2780352672 @default.
• W2083801158 hasConceptScore W2083801158C41008148 @default.
• W2083801158 hasConceptScore W2083801158C530470458 @default.
• W2083801158 hasConceptScore W2083801158C71924100 @default.
• W2083801158 hasLocation W20838011581 @default.
• W2083801158 hasLocation W20838011582 @default.
• W2083801158 hasLocation W20838011583 @default.
• W2083801158 hasLocation W20838011584 @default.

• next